On The Pen

On The Pen

Share this post

On The Pen
On The Pen
Inside the Tirzepatide Supply Number That Could Bring The FDA Lawsuit Crashing Down

Inside the Tirzepatide Supply Number That Could Bring The FDA Lawsuit Crashing Down

On The Pen's avatar
On The Pen
May 02, 2025
∙ Paid
41

Share this post

On The Pen
On The Pen
Inside the Tirzepatide Supply Number That Could Bring The FDA Lawsuit Crashing Down
8
1
Share

There is a moment buried in the April 24 court transcript that deserves much more attention.

At the heart of the lawsuit over compounded tirzepatide lies a simple but explosive discrepancy. The FDA removed tirzepatide from the drug shortage list based on a supply figure provided by Eli Lilly. That figure was used to justify cutting off access to compounded versions of the drug, effectively handing full market control back to Lilly.

But here is the problem…

Keep reading with a 7-day free trial

Subscribe to On The Pen to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 David Knapp
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share